ACS expands lung cancer screening eligibility to ages 50-80 with 20+ pack-years Previous guideline was 55-74 with 30+ pack years

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

Walter J. “Wally” Curran, Jr. has been named the Whitaker Endowed Chief of Piedmont Oncology. This bestowed title is supported by the Piedmont Foundation’s Whitaker Endowment, a fund created by the Atlanta community in tribute to Piedmont’s cancer surgical leader, William Whitaker.

March 28, 2025

Vol.51 No.12

In Brief

John Turchi named inaugural executive director of Indiana University’s Tom and Julie Wood Center for Lung Cancer

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has named John Turchi, the inaugural executive director of the Tom and Julie Wood Center for Lung Cancer Research.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include:

March 28, 2025

Vol.51 No.12

Clinical Roundup

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Two recent studies by researchers from Regenstrief Institute and the Indiana University School of Medicine explore the effect of the pandemic on colorectal cancer screening tests and diagnostic colonoscopies in central Indiana.

March 28, 2025

Vol.51 No.12

In Brief

UA research team receives $1.2M ACS grant to study link between neighborhood environment and cancer risk

A University of Arizona Mel and Enid Zuckerman College of Public Health researcher has received a $1.2 million grant from the American Cancer Society to evaluate potential links between the neighborhood environment and cancer risk.

March 21, 2025

Vol.51 No.11

Clinical Roundup

A post-treatment blood test could inform future cancer therapy decisions, study shows

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.

March 21, 2025

Vol.51 No.11

ACS expands lung cancer screening eligibility to ages 50-80 with 20+ pack-years

Previous guideline was 55-74 with 30+ pack years

YOU MAY BE INTERESTED IN

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

John Turchi named inaugural executive director of Indiana University’s Tom and Julie Wood Center for Lung Cancer

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

UA research team receives $1.2M ACS grant to study link between neighborhood environment and cancer risk

A post-treatment blood test could inform future cancer therapy decisions, study shows

Renew today!

Subscriber content

Never miss an issue!

Login